107th Congress

Hematological Cancer Research Investment and Education Act of 2001

P.L. 107-172 (S. 1094)

Impact of Public Law

Public Law (P.L.) 107-172, the Hematological Cancer Research Investment and Education Act, amends the Public Health Service Act to require:

• The Director of the National Institutes of Health, through the National Cancer Institute, to expand and coordinate blood cancer research programs, particularly with respect to leukemia, lymphoma, and multiple myeloma (the Joe Moakley Research Excellence Program)
• The Secretary of Health and Human Services to establish a related education program for patients and the general public (the Geraldine Ferraro Cancer Education Program)

In addition, P.L. 107-172 authorizes such sums as may be necessary for fiscal year 2002 and each subsequent fiscal year.

Legislative History

On June 22, 2001, Senator Kay Bailey Hutchinson (R-TX) introduced S. 1094, the Hematological Cancer Research Investment and Education Act of 2001. The bill was referred to the Committee on Health, Education, Labor, and Pensions.

On November 8, 2001, the bill was reported out of Committee with an amendment in the nature of a substitute.

On November 16, 2001, the Committee substitute was agreed to by unanimous consent, and passed the Senate by unanimous consent.

On November 19, 2001, the bill was received in the House and referred to the House Committee on Energy and Commerce.

On November 28, 2001, the bill was referred to the House Energy and Commerce Subcommittee on Health.

On April 30, 2002, Representative Michael Bilirakis (R-FL) moved to suspend the rules and pass S. 1094. That motion was agreed to, and the measure passed on voice vote.

On May 6, 2002, the bill was presented to the President and was signed into law on May 14, 2002, becoming P.L. 107-172.